Aktiespot

NovoCure Limited aksje

NVCR

After-hours
$15.82-0.74 (-4.47%)
Post-Market:$16.00+0.18 (+1.14%)
Laster graf...
NovoCure Limited logo

NovoCure Limited

Åpning16.48
Høy16.48
Lav15.65
Volum1.29M
P/EN/A
Markedsverdi1.83B
52-ukers høy19.25
52-ukers lav9.82
Gj.sn. volum1.48M
UtbytteN/A
Beta0.90
EPS-1.53

Om NovoCure Limited aksje

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.

Selskapsinformasjon

Børs: NasdaqGS (NMS)
Sektor: Sundhed
Industri: Medicinsk udstyr
Adresse:
Neuhofstrasse 21
6340 Baar, Switzerland

Analytikernes aksjeanbefalinger

Denne oversikten gir et raskt innblikk i hvordan analytikere vurderer aksjens potensial basert på deres siste analyser og kursmål.

Anbefaling:1.71 - Køb
Laveste kursmål
17.00
7.5%
Gjennomsnittlig kursmål
26.29
66.2%
Median kursmål
27.00
70.7%
Høyeste kursmål
48.00
203.4%

Andre ser også på: